RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+16.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$838M
AUM Growth
+$27.2M
Cap. Flow
-$59.8M
Cap. Flow %
-7.14%
Top 10 Hldgs %
41.9%
Holding
75
New
19
Increased
15
Reduced
20
Closed
20
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$44.5M
2
BHC icon
Bausch Health
BHC
+$40.6M
3
CSLT
CASTLIGHT HEALTH, INC.
CSLT
+$34.3M
4
RAD
Rite Aid Corporation
RAD
+$23.2M
5
HCA icon
HCA Healthcare
HCA
+$22.6M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$48.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$34.3M
4
CELG
Celgene Corp
CELG
+$30.9M
5
AZN icon
AstraZeneca
AZN
+$30.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.72%
2 Miscellaneous 7.42%
3 Technology 2.82%
4 Communication Services 1.03%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AGN
1
DELISTED
Allergan plc
AGN
$50.7M 6.06%
246,398
+74,158
+43% +$14.7M
2013 Q3
2 quarters
HCA icon
2
HCA Healthcare
HCA
$102B
$45.8M 5.47%
872,589
+453,489
+108% +$22.6M
2013 Q2
3 quarters
A icon
3
Agilent Technologies
A
$48.9B
$43.2M 5.16%
+1,080,646
New +$44.5M
2014 Q1
0 quarters
BHC icon
4
Bausch Health
BHC
$2.2B
$39.2M 4.68%
+297,136
New +$40.6M
2014 Q1
0 quarters
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$35.5M 4.24%
513,198
-59,072
-10% -$4.34M
2013 Q2
3 quarters
THC icon
6
Tenet Healthcare
THC
$22B
$33.8M 4.04%
789,562
+328,160
+71% +$14.5M
2013 Q2
3 quarters
GMED icon
7
Globus Medical
GMED
$10.2B
$28.3M 3.37%
1,062,952
-23,685
-2% -$563K
2013 Q2
3 quarters
HTWR
8
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$27.4M 3.27%
291,974
+69,951
+32% +$6.81M
2013 Q2
3 quarters
RAD
9
DELISTED
Rite Aid Corporation
RAD
$23.8M 2.85%
+190,090
New +$23.2M
2014 Q1
0 quarters
TVTY
10
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$23.2M 2.77%
1,354,832
+508,419
+60% +$7.83M
2013 Q3
2 quarters
ARRY icon
11
DELISTED
Array Biopharma Inc
ARRY
$22.9M 2.74%
4,882,930
+422,242
+9% +$2.12M
2013 Q2
3 quarters
BMY icon
12
Bristol-Myers Squibb
BMY
$121B
$21.7M 2.6%
418,500
+17,630
+4% +$938K
2013 Q4
1 quarter
PODD icon
13
Insulet
PODD
$9.36B
$21.7M 2.59%
457,048
+94,012
+26% +$4.16M
2013 Q2
3 quarters
PRTA icon
14
Prothena Corp
PRTA
$432M
$21.4M 2.56%
559,611
+550,511
+6,050% +$17.7M
2013 Q4
1 quarter
CSLT
15
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$20.8M 2.49%
+1,184,347
New +$34.3M
2014 Q1
0 quarters
CMRX icon
16
DELISTED
Chimerix, Inc.
CMRX
$20.4M 2.44%
895,006
+148,601
+20% +$3M
2013 Q2
3 quarters
NUVA
17
DELISTED
NuVasive, Inc.
NUVA
$20M 2.39%
521,301
-29,613
-5% -$1.09M
2013 Q2
3 quarters
JAZZ icon
18
Jazz Pharmaceuticals
JAZZ
$13.7B
$19.8M 2.37%
142,886
-39,675
-22% -$5.97M
2013 Q4
1 quarter
GWPH
19
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$19.2M 2.29%
323,583
-36,394
-10% -$2.16M
2013 Q3
2 quarters
ITCI icon
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$18.2M 2.17%
+1,001,060
New +$18.1M
2014 Q1
0 quarters
PBYI icon
21
Puma Biotechnology
PBYI
$528M
$17.9M 2.14%
172,092
-58,581
-25% -$6.89M
2013 Q2
3 quarters
KYTH
22
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$17.6M 2.1%
443,326
-114,435
-21% -$5.12M
2013 Q2
3 quarters
FOLD icon
23
DELISTED
Amicus Therapeutics
FOLD
$17.6M 2.1%
8,496,538
-151,549
-2% -$379K
2013 Q2
3 quarters
ICPT
24
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$16.9M 2.01%
51,113
-214,836
-81% -$72.5M
2013 Q4
1 quarter
CLDX icon
25
Celldex Therapeutics
CLDX
$2.18B
$15.3M 1.82%
57,596
+31,066
+117% +$11.9M
2013 Q4
1 quarter
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2014 Portfolio in Review

As of Q1 2014, Redmile Group held 75 positions worth $838M, up 3.4% from $810M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $59.8M in Q1 2014, closing 20 positions and reducing 20 holdings. Its most notable exit was Gilead Sciences, an estimated $48.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Agilent Technologies worth $43.2M.

  • Redmile Group's largest Q1 2014 buy was Agilent Technologies: 1,080,646 shares worth $43.2M.
  • Redmile Group added most to HCA Healthcare in Q1 2014, an estimated $22.6M increase.
  • Redmile Group's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $72.5M.
  • Redmile Group fully exited Gilead Sciences in Q1 2014, selling an estimated $48.6M.
  • Redmile Group's ten largest holdings make up 42% of its $838M portfolio in Q1 2014.
  • Redmile Group opened 19 new positions and closed 20 in Q1 2014.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $838M.

Based on Redmile Group's 13F filing for Q1 2014, filed 15 May 2014.